At present, the therapeutic cannabis landscape is characterized by inconsistency. There are states with varying levels of medical cannabis programs and other states with none; doctors who are well-versed in the specificities of medical marijuana, and doctors who are unaware of the existence of the endocannabinoid system. There’s also clinical research that details the efficacy of cannabis in treating specific ailments, but with sweeping differences in the doses of THC or CBD that have been administered. Deducing what constitutes a standard dose can be tricky, to say the least. For a long time, the recommended adage for those experimenting with cannabis medicine has been to “start low, go slow.” A shift is afoot, however, with calls for standardized THC units for both research and clinical purposes.